hypovolemia-->need for fluid therapy
Conditions
Interventions
Trade Name: Sterofundin
Product Name: Sterofundin
Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion
Trade Name: NaCl 0,9 % solution for injection.
Product Name: Sodium
Sponsors
Ghent University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Informed consent patient or legal representative 2. Treating physician decided for fluid bolus of 1 L administered over a 30-60 min time period. 3. Arterial catheter and urinary catheter. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 140 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60
Exclusion criteria
Exclusion criteria: Exclusion criteria 1. Renal replacement therapy 2. <18 y 3. pregnant women 4. lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Primary: Evaluate impact of fluid bolus with 1 L of Sterofundin, Plasma-Lyte ® and NaCl0.9 on acid-base status according to Stewart (SIDa and SIG). ;Secondary Objective: Secondary: • Compare the impact of fluid bolus with 1 L of Sterofundin, Plasma-Lyte and NaCl 0.9% on electrolytes, acid-base status, and osmolality. • Evaluate impact of fluid bolus with 1 L of Sterofundin, Plasma-Lyte and NaCl 0.9% on blood pressure and urine output. ;Primary end point(s): Primary: Evaluate impact of fluid bolus with 1 L of Sterofundin, Plasma-Lyte ® and NaCl on acid-base status according to Stewart (SIDa and SIG). ;Timepoint(s) of evaluation of this end point: SID | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Haemodynamic stability;Timepoint(s) of evaluation of this end point: HR Bloodpressure PH | — |
Countries
Belgium
Contacts
Public ContactDepartment of Anaesthethics
Ghent University Hospital
Outcome results
None listed